Last updated on July 2020

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)


Brief description of study

The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

Clinical Study Identifier: NCT03840902

Find a site near you

Start Over

Lynn Cancer Institute Center

Boca Raton, FL United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

UPMC Cancer Center

Pittsburgh, PA United States
  Connect »

Bendigo Hospital

Bendigo, Australia
  Connect »

Austin Health

Heidelberg Heights, Australia
  Connect »

Sunshine Hospital

St Albans, Australia
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Jeroen Bosch Ziekenhuis

's Hertogenbosch, Netherlands
  Connect »

Martini ziekenhuis

Groningen, Netherlands
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.